Newbury Pharmaceuticals AB (NEWBRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) has a cash flow conversion efficiency ratio of 0.072x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.26 Million ≈ $243.21K USD) by net assets (Skr31.30 Million ≈ $3.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Newbury Pharmaceuticals AB to measure how many days the company can operate on defensive assets alone.
Newbury Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Newbury Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Newbury Pharmaceuticals AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rossi Residencial S.A
SA:RSID3
|
-0.033x |
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
N/A |
|
Ecoslops SA
PA:ALESA
|
0.259x |
|
Rockworth Public Company Limited
BK:ROCK
|
0.017x |
|
PLENUM AG NA O.N.
F:PLEK
|
N/A |
|
Digitalist Group Oyj
HE:DIGIGR
|
0.017x |
|
Strategic Energy Resources Limited
F:EB8
|
-0.012x |
|
NGS Group AB (publ)
ST:NGS
|
0.030x |
Annual Cash Flow Conversion Efficiency for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual cash flow conversion efficiency of Newbury Pharmaceuticals AB from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Newbury Pharmaceuticals AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-08-31 | Skr51.92 Million ≈ $5.59 Million |
Skr-23.71 Million ≈ $-2.55 Million |
-0.457x | +2.92% |
| 2023-08-31 | Skr49.38 Million ≈ $5.31 Million |
Skr-23.23 Million ≈ $-2.50 Million |
-0.470x | -115.64% |
| 2022-08-31 | Skr68.77 Million ≈ $7.40 Million |
Skr-15.00 Million ≈ $-1.61 Million |
-0.218x | -106.38% |
| 2021-08-31 | Skr38.47 Million ≈ $4.14 Million |
Skr-4.07 Million ≈ $-437.57K |
-0.106x | -- |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.